Wharton Profs. to Present on Corporate Governance, Vaccine Uptake and Housing Market at Wharton Seminars for Business Journalists Virtual Program, June 2
Share Article PHILADELPHIA (PRWEB) April 21, 2021 What: The Wharton School is pleased to invite business journalists to apply for the next virtual Wharton Seminars for Business Journalists program. The June 2021 program will feature Wharton professors Katy Milkman, Ben Keys and Mary-Hunter McDonnell who will present on “The Science of Behavior Change,” “Unpacking the COVID-19 Housing Bubble” and “How Corporate America Responds to Contentious Social Environments, respectively.
Through intensive lectures and expert Q&A the Seminars, led by the Wharton School’s most prominent professors, help reporters gain a better understanding of key business and economic issues. For more than 50 years, the Seminars have offered participants an opportunity to expand
Senior Fintech/Healthcare Executive Joins Praesidian Capital as Strategic Advisor and Operating Partner
News provided by
Share this article
Share this article
NEW YORK, April 20, 2021 /PRNewswire/ Praesidian Capital, a leading middle market private equity firm today announced that Arun Gowda will be joining the firm as a Strategic Advisor and Operating Partner. Jason Drattell, Praesidian Founder stated: Arun has a well-established track record in the financial services sector and has been advising and investing with Praesidian for a number of years. We are excited to have him formally join the group, emphasizing transactions in Fintech and healthcare.
Arun Gowda
The NBER coordinates fellowship programs for PhD students and post doctoral researchers supported by several federal and foundation funders. Calls for most fellowships are posted in the fall, with closing dates in December. During academic year 2020-21, the NBER was able to offer fellowship support for graduate students studying the economics of aging, behavioral macroeconomics, energy economics, gender in the economy, health economics, and retirement and disability, and postdoctoral research support for study of aging and health, the aging workforce, disability, fiscal policy, retirement security, and tax competition. The NBER also offers a postdoctoral fellowship for a researcher who is a member of a group that is historically under-represented in economics, or who is studying diversity in the economics profession.
Patient Square Capital Hires Fund Partnerships Veteran Jake Cabala
News provided by
Share this article
Share this article
MENLO PARK, Calif., April 20, 2021 /PRNewswire/ Patient Square Capital, a dedicated health care investment firm, announced today that Jake Cabala has joined as a Partner, where he will be the Head of Fund Partnerships and primarily be responsible for the firm s capital formation, co-invest syndication, and investor relations functions.
Mr. Cabala brings over 14 years of operating, capital formation, and fund partnership experience to Patient Square. Previously, Mr. Cabala was the Head of Capital Formation at Golden Gate Capital, where he focused both on building and maintaining partnerships with Golden Gate s limited partners and developing new asset management platforms within the firm s financial services vertical.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Affinivax Appoints Stuart Chaffee, PhD, as Chief Business Officer
April 20, 2021 GMT
Affinivax Chief Business Officer Stuart Chaffee PhD (Photo: Business Wire)
CAMBRIDGE, Mass. (BUSINESS WIRE) Apr 20, 2021
Affinivax, Inc. (“Affinivax”), a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS™ (Multiple Antigen Presenting System) platform, today announced that Stuart Chaffee, PhD, has joined the company as Chief Business Officer. Dr. Chaffee brings to Affinivax extensive experience in business operations, finance and corporate development, including previous roles as Chief Business Officer and CFO at Praxis Precision Medicines and as Head of Business Operations and Co-founder of Kymera Therapeutics.